Company profile: Zealand Pharma
1.1 - Company Overview
Company description
- Provider of peptide-based medicines and novel specialty drug candidates, leveraging leading-edge expertise and partnerships. Offerings include dasiglucagon for severe hypoglycemia (with Novo Nordisk), survodutide for obesity and MASH (with Boehringer Ingelheim), dapiglutide, and devices such as the investigational bihormonal iLet bionic pancreas (with Beta Bionics) and a continuous infusion pump for congenital hyperinsulinism (with DEKA Research).
Products and services
- Dapiglutide: A GLP-1/GLP-2 receptor dual agonist in clinical trials, leveraging combined receptor activation for potential therapeutic benefits under ongoing evaluation
- Dasiglucagon: A glucagon analog used for the treatment of severe hypoglycemia in diabetes patients, developed in partnership with Novo Nordisk, supporting therapeutic intervention when severe hypoglycemic events occur
- Survodutide: A long-acting glucagon/GLP-1 receptor dual agonist being developed with Boehringer Ingelheim for obesity and MASH, engaging both receptor pathways to provide durable pharmacologic activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Zealand Pharma
Navamedic
HQ: Sweden
Website
- Description: Provider of pharmaceutical and medtech products, marketing to patients, hospitals and pharmacies. Offers prescription and OTC medicines and healthcare products; the Sippi next-generation digital urine meter; and a portfolio including Eroxon gel to help men achieve an erection, Flexilev for Parkinson’s, Absolut Torr antiperspirant, MedMade micronutrient supplements, and PKU and obesity education/support programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Navamedic company profile →
CB Fleet
HQ: United States
Website
- Description: Provider of feminine care products for personal hygiene and comfort and over-the-counter (OTC) healthcare products addressing common health concerns, serving as a manufacturer, marketer, and distributor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CB Fleet company profile →
Recordati
HQ: Italy
Website
- Description: Provider of medications and treatment options across specialty and primary care, consumer healthcare, and rare diseases, focusing on the development and distribution of therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Recordati company profile →
Pernix Therapeutics
HQ: United States
Website
- Description: Provider of branded and generic pharmaceutical products for the pediatric market, specializing in the sales, marketing, and development of products designed to improve children's health and well-being, including offerings in allergy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pernix Therapeutics company profile →
Arrowhead Pharmaceuticals
HQ: United States
Website
- Description: Provider of RNAi therapeutics for genetically driven diseases with protein overproduction, leveraging the TRiM platform for ligand-mediated, tissue-specific delivery. Pipeline includes plozasiran (ARO-APOC3) for hypertriglyceridemia, zodasiran (ARO-ANG3) for mixed dyslipidemia, and ARO programs targeting RAGE, MUC5AC, and MMP7 for inflammatory and muco-obstructive lung diseases and idiopathic pulmonary fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arrowhead Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Zealand Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Zealand Pharma
2.2 - Growth funds investing in similar companies to Zealand Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Zealand Pharma
4.2 - Public trading comparable groups for Zealand Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →